Inozyme Pharma, Inc. (INZY)
NASDAQ: INZY · Real-Time Price · USD
1.005
+0.005 (0.53%)
Mar 14, 2025, 11:43 AM EDT - Market open
Inozyme Pharma Employees
Inozyme Pharma had 67 employees as of December 31, 2024. The number of employees increased by 8 or 13.56% compared to the previous year.
Employees
67
Change (1Y)
8
Growth (1Y)
13.56%
Revenue / Employee
n/a
Profits / Employee
-$1,522,746
Market Cap
64.56M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 67 | 8 | 13.56% |
Dec 31, 2023 | 59 | 3 | 5.36% |
Dec 31, 2022 | 56 | 6 | 12.00% |
Dec 31, 2021 | 50 | 12 | 31.58% |
Dec 31, 2020 | 38 | - | - |
INZY News
- 4 days ago - Inozyme Pharma Reports Full Year 2024 Financial Results and Announces Strategic Prioritization of ENPP1 Deficiency Pivotal Program and Recent Business Highlights - GlobeNewsWire
- 18 days ago - Inozyme Pharma to Present at the TD Cowen 45th Annual Health Care Conference - GlobeNewsWire
- 21 days ago - Inozyme Pharma to Present Recently Announced Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency at CHOP Cardiology 2025 - GlobeNewsWire
- 3 months ago - Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference - GlobeNewsWire
- 4 months ago - Inozyme Pharma to Present at Upcoming Investor Conferences - GlobeNewsWire
- 4 months ago - Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights - GlobeNewsWire
- 5 months ago - Inozyme Pharma Announces Positive Interim Data from Phase 1 SEAPORT 1 Trial of INZ-701 - GlobeNewsWire
- 5 months ago - Inozyme Pharma Announces Presentation of Interim Data from Phase 1 SEAPORT 1 Trial at the Upcoming American Society of Nephrology (ASN) Kidney Week 2024 - GlobeNewsWire